In conclusion, our study supports the potential of dual EZH2 and CDK4/6 blockade as a promising therapeutic strategy for GBM, demonstrating superior efficacy compared to individual monotherapies across various models via perturbation of ER-mitochondrial homeostasis. Here, CDK4 is linked to glioblastoma.